Collplant Biotechnologies Ltd
NASDAQ:CLGN
Intrinsic Value
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of t... [ Read More ]
The intrinsic value of one
CLGN
stock under the Base Case scenario is
44.9474
USD.
Compared to the current market price of 5.3601 USD,
Collplant Biotechnologies Ltd
is
Undervalued by 88%.
Collplant Biotechnologies Ltd's market capitalization is 61.4m USD.
CLGN stock price is 5.3601 USD.
CLGN stock price (5.3601 USD) is 88% less than its Intrinsic Value (44.9474 USD).
CLGN stock price (5.3601 USD) is 91% less than its Relative Value (59.9173 USD). Open Relative Valuation
CLGN has upside potential of 109% compared to the average analyst price target.
Open Wall St Estimates
CLGN's Revenue has been growing by an exceptional 21% per year for the last 3 years.
CLGN's Revenue has grown by an exceptional 3 553% over the past 12 months.
CLGN's ROE (Return on Equity) has significantly increased in the last 3 years from -98% to -23%, and is approaching profitability.
CLGN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -106% to -128%, and is approaching profitability.
CLGN has positive Gross Profit for the last twelve months.
CLGN's Altman Z-Score is very high and is equal to 3.23.
CLGN has negative Operating Income for the last twelve months.
CLGN has negative Net Income for the last twelve months.
CLGN's ROE (Return on Equity) for the past 12 months is negative and is equal to -23%.
CLGN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -128%.
CLGN's Revenue is forecast to grow at a rate of 97% per year over the next 3 years.
CLGN has negative Free Cash Flow for the last twelve months.
CLGN has negative three-year average ROE (Return on Equity): -38%. The company is not efficient at transforming stockholders' equity into net income.
CLGN has negative three-year average ROIC (Return on Invested Capital): -170%. The company is not efficient at using invested capital to generate operating income.
CLGN's short-term assets (28m USD) exceed its short-term liabilties (3m USD).
CLGN's long-term assets (34m USD) exceed its long-term liabilties (6m USD).
CLGN's D/E (Debt to Equity) is very low and is equal to 0.
Valuation Backtest
Collplant Biotechnologies Ltd
Run backtest to discover the historical profit from buying and selling
CLGN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Collplant Biotechnologies Ltd
Balance Sheet Decomposition
Collplant Biotechnologies Ltd
| Current Assets | 28m |
| Cash & Short-Term Investments | 26.7m |
| Receivables | 393k |
| Other Current Assets | 955k |
| Non-Current Assets | 6.1m |
| PP&E | 5.9m |
| Intangibles | 188k |
| Other Non-Current Assets | 57k |
| Current Liabilities | 3.3m |
| Accounts Payable | 2.6m |
| Accrued Liabilities | 624k |
| Non-Current Liabilities | 2.5m |
| Other Non-Current Liabilities | 2.5m |
Earnings Waterfall
Collplant Biotechnologies Ltd
|
Revenue
|
11m
USD
|
|
Cost of Revenue
|
-1.1m
USD
|
|
Gross Profit
|
9.8m
USD
|
|
Operating Expenses
|
-16.5m
USD
|
|
Operating Income
|
-6.6m
USD
|
|
Other Expenses
|
-373k
USD
|
|
Net Income
|
-7m
USD
|
Free Cash Flow Analysis
Collplant Biotechnologies Ltd
CLGN Profitability Score
Profitability Due Diligence
Collplant Biotechnologies Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Collplant Biotechnologies Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
CLGN Solvency Score
Solvency Due Diligence
Collplant Biotechnologies Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Collplant Biotechnologies Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLGN Price Targets Summary
Collplant Biotechnologies Ltd
According to Wall Street analysts, the average 1-year price target for
CLGN
is 11.22 USD
with a low forecast of 11.11 USD and a high forecast of 11.55 USD.
Shareholder Return
CLGN Price
Collplant Biotechnologies Ltd
| Average Annual Return | 25.65% |
| Standard Deviation of Annual Returns | 58.52% |
| Max Drawdown | -81% |
| Market Capitalization | 61.4m USD |
| Shares Outstanding | 11 452 700 |
| Percentage of Shares Shorted | 0.14% |
Company Profile
Collplant Biotechnologies Ltd
Country
Industry
Market Cap
Dividend Yield
Description
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Contact
IPO
Employees
Officers
The intrinsic value of one
CLGN
stock under the Base Case scenario is
44.9474
USD.
Compared to the current market price of 5.3601 USD,
Collplant Biotechnologies Ltd
is
Undervalued by 88%.
You don't have any saved screeners yet
